Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Michael D. Tsymliakov"'
Autor:
Maria S. Volkova, Alexander M. Efremov, Elena N. Bezsonova, Michael D. Tsymliakov, Anita I. Maksutova, Maria A. Salykina, Sergey E. Sosonyuk, Elena F. Shevtsova, Natalia A. Lozinskaya
Publikováno v:
Molecules, Vol 27, Iss 21, p 7462 (2022)
2,3-Dihydroindoles are promising agents for the synthesis of new compounds with neuroprotective and antioxidant properties. Usually, these compounds are obtained by direct reduction of the corresponding indoles containing acceptor groups in the indol
Externí odkaz:
https://doaj.org/article/8dbcec8864c348d69da9895ec2b97a5d
Autor:
Daniil R. Bazanov, Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Victoria Yu. Savitskaya, Sergey E. Sosonyuk, Yulia A. Gracheva, Michael Yu. Seliverstov, Natalia A. Lozinskaya, Gelina S. Kopeina
Publikováno v:
Pharmaceuticals, Vol 15, Iss 4, p 444 (2022)
The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are a
Externí odkaz:
https://doaj.org/article/86381fec34274d868b2c6af77b718cf2
Autor:
Michael D. Tsymliakov, Anita I. Maksutova, Elena N. Bezsonova, Daria V. Zakharova, Yuri K. Grishin, Victor A. Tafeenko, Sergey E. Sosonyuk, Natalia A. Lozinskaya
Publikováno v:
Mendeleev Communications. 33:121-123
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc113f8974e085b8be122a6732ccb5af
https://doi.org/10.1016/j.mencom.2023.01.038
https://doi.org/10.1016/j.mencom.2023.01.038
Autor:
N. A. Lozinskaya, Egor V. Savin, Nikolay V. Pervushin, Anita I. Maksutova, Gelina S. Kopeina, Michael D. Tsymliakov, Daniil R. Bazanov, S. E. Sosonyuk
Publikováno v:
Medicinal Chemistry Research. 30:2216-2227
p53-MDM2/MDMX interaction inhibitors represent the prospective agents for targeted anticancer therapy in tumors expressing wild-type p53 protein. Imidazoline-based MDM2-targeted inhibitors of such type, nutlins, contain halogen-substituted phenyl rin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::289d249cdc72c1d7fe79c6a5faaf6593
https://doi.org/10.1007/s00044-021-02802-w
https://doi.org/10.1007/s00044-021-02802-w